RESUMO
For forensic and clinical toxicologic purposes, cannabis consumption is screened using easy-to-handle immunoassays. The sensitivity and specificity of these immunoassays have not yet been established in samples from volunteers receiving oral synthetic tetrahydrocannabinol or cannabis extracts using liquid chromatography-mass spectrometry/mass spectrometry as the reference method. Urine samples were collected in an open, randomized, single-center, three-period crossover study including 18 healthy male volunteers given either 20 mg synthetic tetrahydrocannabinol (Marinol) as a control substance or five different types of Cannabis sativa extracts.
Assuntos
Canabinoides/urina , Administração Oral , Adulto , Calibragem , Canabinoides/administração & dosagem , Cannabis/química , Cromatografia Líquida de Alta Pressão , Reações Cruzadas , Dronabinol/administração & dosagem , Dronabinol/urina , Humanos , Hidrólise , Imunoensaio , Masculino , Extratos Vegetais/farmacocinética , Psicotrópicos/administração & dosagem , Psicotrópicos/urina , Controle de Qualidade , Curva ROC , Padrões de Referência , Soluções , Espectrometria de Massas em Tandem , Adulto JovemRESUMO
A novel high-performance liquid chromatographic separation method with tandem-mass spectrometry detection was developed for the simultaneous determination of Delta(9)-tetrahydrocannabinol (THC) and its major metabolites 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC) and 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) as well as the components cannabidiol (CBD) and cannabinol (CBN) in human EDTA-plasma and urine. Run time was 25 min. Lower limit of quantification was 0.2 ng/ml. The coefficients of variation of all inter- and intra-assay determinations were between 1.3 and 15.5%. The method was successfully applied to the determination of cannabinoids in human plasma and human urine after administration of Delta(9)-tetrahydrocannabinol or Cannabis sativa extracts.